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Abstract 
Tumour−specific, immuno−based therapeutic interventions can be considered as safe and 
effective approaches for cancer therapy. Exploitation of nano−vaccinology to intensify 
the cancer vaccine potency may overcome the need for administration of high vaccine 
doses or additional adjuvants and therefore could be a more efficient approach. Carbon 
nanotube (CNT) can be described as carbon sheet(s) rolled up into a cylinder that is 
nanometers wide and nanometers to micrometers long. Stemming from the observed 
capacities of CNTs to enter various types of cells via diversified mechanisms utilising 
energy−dependent and/or passive routes of cell uptake, the use of CNTs for the delivery 
of therapeutic agents has drawn increasing interests over the last decade. Here we review 
the previous studies that demonstrated the possible benefits of these cylindrical 
nano−vectors as cancer vaccine delivery systems as well as the obstacles their clinical 
application is facing.   
 
Keywords: Cancer immunotherapy, antigen presenting cells, nanomedicine, vaccine 
delivery, carbon nanotube. 
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1. Introduction 
Conventional treatments for cancer include surgery, chemotherapy and 
radiotherapy. Surgical operations can be associated with complications arising from 
damaging the tissues surrounding the tumour site. Radiotherapy, which relies on the 
application of ionising radiation to the tumour sites, leading to DNA damage and 
inhibition of cancer cell proliferation, can also affect the division of normal cells such as 
blood forming cells in bone marrow [1, 2]. In addition, cancer surgery and radiotherapy 
are only efficient in treating localised tumour. In cases where cancer cells have 
metastasised, i.e. gained access to sites distal to the primary tumour, chemotherapeutic 
drugs, e.g. cisplatin, are administered to slow down cancer cell proliferation and prolong 
patient survival [3]. Chemotherapeutic agents are typically non−specific and can also 
inhibit the proliferation of normal cells leading to serious side effects such as 
myelosuppression and immunosuppression [2, 4], which can limit the administration of 
higher doses to achieve better efficacy.  
The human body is equipped with a number of defensive mechanisms that can be 
harnessed to fight the cancer cells. In fact, it is hypothesised that the immune system is in 
a continuous state of cancer immune surveillance [5]. According to this concept, 
professional antigen presenting cells (APCs) such as the dendritic cells (DCs) sample all 
tissues for the presence of stress signals such as danger−associated molecular patterns 
which are upregulated in tumour tissues. The presence of such stress signals activates the 
innate immune system and the resulting immune response keeps tumour growth in check. 
Once the cancer cells acquire mutations that let them escape the control by the immune 
system they acquire the ability to establish tumours. Given this, the use of 
immunotherapy for cancer has attracted significant interests over the last decades 
culminating in numerous clinical trials [6].  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
5 
 
Cancer vaccines are one such intervention. Like traditional vaccines against 
infectious disease, cancer vaccines are comprised of cancer cell−derived antigens 
formulated in such a fashion as to provoke a potent immune response. Typically the 
antigenic payload of these vaccines are either mutated proteins arising as a direct result 
or as a byproduct of tumorigenesis (so called neo antigens), proteins which are 
overexpressed in tumours or proteins which are the result of aberrant expression of 
embryonic genes in tumours [7-9]. The anti−tumour immune responses elicited by the 
cancer vaccine is aimed to systemically target the cancer cells throughout the whole 
body; hence cancer immunotherapy can be used to treat metastatic tumours [10]. 
Moreover, immunisation with cancer vaccines can induce persistent T cell 
memory−specific against the tumour cells, providing long−lived protection and 
prolonged patient survival [11].  
Unfortunately, while in preclinical models cancer vaccine have proven efficacious 
there has been limited progress in the development of human cancer vaccines, with a 
number of high profile candidates failing to meet their end points in clinical trials [12]. 
This is, in part due to the failure to overcome tumour−induced immunosuppression [13, 
14]. However, there has been a surge of renewed interest in the field since the advent of 
checkpoint blockade and increased understanding of the immune suppressive tumour 
micro−environment [15].         
It is likely that a successful cancer vaccine will be composed of three components: 
the antigen, the adjuvant and the delivery vehicle. This regime may or may not be 
supplemented with a checkpoint inhibitor. Speculating further it may be proposed that 
cancer vaccines will require novel formulations distinct from formulations previously 
used for infectious disease (such as alum absorbed antigen) as cancer immunity will 
primarily be driven by cell−mediated cytotoxic responses rather than antibody−mediated 
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humoral responses [6]. This review discusses one such formulation; carbon nanotubes in 
the context of cancer vaccines. 
2. Carbon nanotubes (CNTs) as nanocarriers 
CNTs are synthetic allotropes of carbon. Allotropy is described as the chemical 
elements ability to exist in more than one form. Three allotropic forms have been 
identified for carbon. The natural carbon allotropes include diamond, graphite (several 
layers of graphene) and amorphous carbon (non−crystalline form of carbon) [16]. The 
synthetic carbon allotropes that have been discovered include fullerene (sphere of carbon 
atoms) [17], graphene (single layer of graphite) [18] and CNT (cylinder consisting of 
rolled graphene layer(s)) (Fig. 1.) [19]. Morphologically, CNTs can be described as 
cylinders that are nanometers wide and nanometers to micrometers long, consisting of 
graphene rolled up in the form of single or multiple concentric layer(s) that are referred 
to as single−walled CNT (SWNT) or multi−walled CNT (MWNT), respectively [20]. 
 
 
 
 
 
 
 
 
Fig. 1. Different allotropes of carbon.  
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2.1 Spheres vs Tubes vs Sheets as nanocarriers 
In terms of carbonaceous nanomaterials two carriers have been widely employed, 
namely CNT and the carbon nanosheet Graphene oxide (GO). Unlike most other 
materials there has been minimal work assessing the spherical form of carbon: fullerenes, 
as a carrier [21]. Therefore, it is difficult to attribute the observed effects to morphology 
or material composition when comparing CNT to other carriers. However, morphology 
dependant behaviour can be observed in other systems. For instance, Trewyn et al. 
compared the cellular uptake of silica nanoparticles that were either tube−shaped (100 
nm wide and 600 nm long) or spherical shaped (115 nm in diameter) of comparable 
surface charges [22]. The tube−shaped silica nanoparticles demonstrated higher uptake 
by CHO cells or fibroblast cells, in vitro, compared to the spherical ones. Similarly, 
Huang et al. have reported that internalisation of rod−shaped silica nanoparticles (100 nm 
wide and 450 nm long) by the epithelial A375 line in vitro was higher compared to the 
spherical nanoparticles (100 nm in diameter) [23]. Whether the carrier's 
morphology−dependent cellular uptake affects the biological response induced by the 
loaded cargo demands future investigations. In light of these findings and hypotheses, 
comparative studies need to be carried out to investigate the cellular uptake and 
immunogenicity of CNTs versus spherical nanoparticles, ideally fullerenes but also the 
extensively studied poly(lactic−co−glycolic acid) (PLGA) nanoparticles and liposomes. 
The findings of such studies will undoubtedly contribute to the nanovaccinology field 
and further searches for nano−carriers with optimal morphological properties capable of 
efficient vaccine delivery.       
The other commonly used carbon allotrope is the carbon nanosheet, GO [24-27]. 
The use of GO, as a cancer vaccine carrier, has been assessed by several groups. Yue et 
al. demonstrated that a subcutaneous injection of GO−OVA in C57BL/6 mice showed 
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significantly elevated OVA−specific CTL response in comparison to OVA alone [28]. 
Furthermore, in a thymoma model immunisation of the aforementioned mice with 
GO−OVA was more efficient than OVA alone in limiting the growth of E.G7−OVA 
lymphoma cells. Testing the ability to induce protective anti−tumour immunity, Sinha et 
al. have reported that compared to C57BL/6 mice immunised with OVA alone, mice 
vaccinated with dextran−functionalised GO−OVA showed smaller tumour sizes after 
challenging with subcutaneous injection of OVA−expressing melanoma B16 cells [29]. 
These findings presented GO as a competent vaccine nanocarrier. Both CNTs and GO 
possess attractive properties of being able to incorporate the biomolecules of interest via 
simple surface adsorption. However, the proficiency of these carbon nanosheets (GO) 
compared to the CNTs in delivering vaccines remains in question. Zhang et al. have 
demonstrated that radiolabelled oxidised MWNTs were taken up in higher amounts 
compared to radiolabelled GO, by HeLa cells in vitro [30]. The degree of cellular uptake 
is a key, but is not the only, factor determining the intensity of elicited immune response. 
Proper comparative assessment of CNTs and GO uptake by the APCs and the subsequent 
impact on the induced immune response will assist future researches on further 
developing carbon nanocarriers suitable for vaccine delivery. 
2.2 Mechanisms of CNTs' cellular uptake 
Pristine (unmodified) CNTs are hydrophobic in nature and are thus characterised 
by their low dispersibility and high tendency to form aggregates in aqueous media. CNT 
bundle formation is attributed to the non−covalent interactions between the nanotubes 
such as the π−π stacking that occur between the aromatic rings of adjacent nanotubes. 
Thereby, it was essential to find chemical approaches that can improve the CNTs 
biocompatibility by enhancing the CNTs degree of individualisation and dispersibility in 
physiological fluids. The chemical approaches that have been applied to functionalise 
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CNTs can be classified into covalent and non−covalent functionalisations [31, 32]. For 
instance, utilising covalent functionalisation, pristine CNTs sonication in a mixture of 
acids (e.g., sulphuric and nitric acids [33, 34]) can incorporate carboxylic groups that can 
be activated using carbodiimide−based approach which can be further derivatised with 
amine-terminated linkers yielding functionalised CNT with improved hydrophilicity [32]. 
Relying on non−covalent interactions, Zheng et al. have shown that SWNT dispersibility 
in aqueous solution was improved by sonication with single stranded DNA (ssDNA) 
[35]. Wang et al. have also demonstrated that bovine serum albumin non−covalent 
conjugation with oxidised MWNTs led to an enhanced dispersibility in 
phosphate−buffered saline [36].  
In order to assess the possible benefits that can be obtained from using CNTs as 
therapeutics delivery vector, it was important to study the mechanisms by which these 
nanoscopic scaffolds can enter the cells. CNTs have demonstrated high ability to enter 
various types of cells [37-39]. It has been previously reported that polymeric spherical 
nanoparticles, e.g. PLGA nanoparticles, mainly utilise energy−dependent mechanisms of 
cellular uptake rather than energy−independent ones [23, 40, 41]. However, there is good 
data to suggest the efficiency and uptake route of CNTs is highly dependent on 
morphology and surface chemistry. 
For instance, Shi Kam et al. showed that the cellular uptake of fluorescent labelled 
streptavidin protein, by HL60 leukaemia cells, was improved by its conjugation to 
oxidised SWNTs [42, 43]. The uptake of the SWNT−streptavidin conjugate was reduced 
when cells were placed at 4 ◦C, suggesting that the internalisation of SWNT was carried 
out via endocytosis, which is an energy−dependent mechanism. In addition, staining the 
endosomes with a fluorescent marker followed by confocal microscopy revealed the 
presence of SWNT−streptavidin in the endocytic vesicles of these cells, which further 
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supported the proposed endocytosis mechanism. Relying on the detection of SWNTs 
intrinsic near infra−red fluorescence to assess the cellular uptake, Cherukuri et al. have 
shown that the uptake of pristine SWNTs, dispersed in Pluronic surfactant, by mouse 
macrophage cells in vitro was dramatically reduced by incubating the cells at 27 ◦C rather 
than 37 ◦C [44]. This finding also suggested an endocytosis−dependent mechanism for 
SWNTs uptake. 
On the other hand, other studies have suggested that the cellular uptake of CNTs is 
mainly achieved via passive diffusion through the cell membrane. Pantarotto et al. have 
demonstrated that amine−functionalised SWNTs improved the internalisation of 
fluorescent labelled peptide by human 3T6 fibroblasts incubated at 37 ◦C, as determined 
by epifluorescence microscopy that also revealed the presence of the SWNTs in the 
nucleus [45]. Inhibiting the metabolic functions of cell by incubation at 4 ◦C or treatment 
with sodium azide did not affect the cellular uptake of the SWNTs, which suggested an 
energy−independent mechanism of cell uptake. The CNT's ability to penetrate through 
the cell membrane, like nano−needles, could be explained by the nanosyringe mechanism 
theoretically simulated by Lopez et al. for nanotubes insertion into the lipid bilayer [46]. 
Molecular dynamics presented by Lopez et al. showed that hydrophobic nanotube with 
hydrophilic tips firstly adsorbs, in a horizontal plane, onto a model membrane [46]. 
Partial insertion of the nanotube into the model bilayer is then followed by spontaneous 
change in the nanotube orientation from the horizontal into the vertical alignment, 
forming a transmembrane pore−like orientation through the bilayer. Insertion into the 
membrane bilayer could be then followed by translocation to the intracellular 
compartments as reported by Pantarotto et al. In another study, further investigation of 
the energy−independent CNT uptake was carried out, and confocal microscopy images 
revealed the internalisation of fluorescent labelled and amine–functionalised MWNTs by 
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fungal (Saccharomyces Cerevisiae) and yeast cells (Cryptococcus neoformans) [47]. The 
functionalised MWNTs internalisation by these prokaryotic cells (which normally lack 
the ability to carry out active processes such as endocytosis) highlighted the MWNTs' 
utilisation of mechanisms other than endocytosis for cell entry. In addition, it was shown 
that Jurkat leukaemic T cells incubation with the functionalised MWNTs at 4 ◦C in the 
presence of sodium azide did not inhibit the cellular uptake of MWNTs, which confirmed 
the involvement of passive cellular uptake mechanism. The contradicting mechanisms of 
CNTs cellular uptake reported by different authors could be attributed to the properties of 
the CNTs used in these studies such as the CNTs' degree of individualisation and 
dispersibility in the cell culture media, which is highly dependent on the CNTs' 
functionalisation density.  
Mu et al. have studied the uptake of functionalised MWNTs by HEK293 epithelial 
cells using TEM [48]. In this study, single MWNT were imaged penetrating the cell 
membrane, while MWNTs bundles were found intracellularly surrounded by endosomal 
membrane. Single MWNT released from the MWNTs bundle entrapped in endosomes 
were also imaged while penetrating the endosomal membrane, to enter the cytosol.  
Collectively, from these studies it could be concluded that CNTs can access the 
intracellular compartments via more than one mechanism of cell entry. This could be 
attributed to the length to width ratio of the CNTs that allows the, nanoneedle−shaped, 
CNTs to passively penetrate the cell membrane utilising the hypothesised and 
experimentally demonstrated nanosyringe mechanism, in addition to the active 
endocytosis mechanism. The role of uptake cannot be understated as the ultimate goal of 
cancer vaccines is to induce a tumour−specific cytotoxic and memory CD8+ T cells 
responses, capable of eradicating the established tumours and providing long−term 
protection, respectively [12]. Promoting antigen translocation to the DC's cytosol, where 
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proteasomal processing occurs, could enhance antigen cross−presentation and, 
subsequently, the induction of antigen−specific CD8+ T cell response [49]. The fact that 
CNTs can passively diffuse through the cell membrane and reach the cytosol or leak 
through the endosomes into the cytosol following internalisation via endocytosis could 
suggest that CNTs are qualified, as delivery vector, to translocate their loaded antigen to 
the cytosolic compartments (Fig. 2.) [45, 47, 48]. The CNTs ability to penetrate the cell 
membrane might be assigned to their nanoneedle−like structure which arises from their 
high aspect ratio (length to width ratio) [46]. Nevertheless, endosomal membrane 
disruption associated with CNTs endosomal escape could induce cell damage [50, 51]. 
Membrane disruption could activate NLRP3 inflammasome and consequently induce 
pyroptotic cell death [50, 51], and is a concern that should not be overlooked on 
designing a CNT−based vaccine delivery system. 
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Fig. 2. Proposed pathways for MHC presentation of CNTs−delivered antigens. CNTs could 
deliver the incorporated antigen to the cytosol of the DCs, via two proposed routes, where 
degradation by proteasome and subsequent MHC class I presentation occur. The ability of 
CNT−antigen conjugates to passively diffuse through the cell membrane could directly deliver 
the loaded antigen to the cytosol. Alternatively, following the active uptake of CNT−antigen 
conjugates by DCs and the subsequent endosomal escape; the incorporated antigen could gain 
entry into the cytosol. In addition, overcoming the need for endosomal escape, antigenic 
fragments yielded from antigens processed in the endosomes by endosomal proteases could be 
loaded onto the MHC class I molecules recycled from the plasma membrane. Furthermore, 
professional cross−priming DCs could translocate endocytosed antigenic cargo to the MHC class 
I pathway via the utilisation of cross−presentation mechanism. Lysosomal degradation of 
CNTs−delivered antigens that fail to escape the endosomes could be followed by MHC class II 
presentation. 
 
2.3 CNTs' Biocompatibility in vitro 
2.3.1 Effect of CNTs' chemical functionalisation  
Residual transition metal catalysts such as iron, cobalt or nickel contained in the 
pristine CNTs can catalyse the intracellular formation of free radicals and oxidative stress 
leading to cytotoxic effects. For instance, treating HEK293 human kidney embryo cells 
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with pristine SWNTs induced cell apoptosis and reduced cell proliferation [52], 
additionally incubating Calu−3 human epithelial cells with pristine MWNTs significantly 
reduced cell viability [53]. However, chemically functionalised CNTs have shown better 
biocompatibility profiles compared to the pristine material. This could be attributed to the 
fact that exposing pristine CNTs to chemical reactions followed by successive washing in 
organic solvents with the aid of bath sonication help in removing metal catalysts 
adsorbed onto the CNTs wall. In addition, chemical reactions, such as bath 
sonication−assisted acid oxidation, that generate surface defects onto the CNTs help in 
removing trapped metal catalysts [54].  
Coccini et al. have shown that acid−oxidised MWNTs possessed lower metal content 
and exerted minor effects on the cell viability compared to the pristine MWNTs 
following incubation with the epithelial A549 cells at 1 μg/ml [55]. However, increasing 
the oxidised MWNT concentration in the culture media was accompanied by dramatic 
decrease in the A549 cells viability. Vuković et al. have reported that treating fibroblast 
L929 cells with pristine MWNTs at concentrations ranging 3−12.5 μg/ml significantly 
reduced the cell proliferation, while incubation with carboxylic or amine−functionalised 
MWNTs did not show this effect [56]. Despite this, the proliferation of the L929 cells 
incubated with the functionalised MWNTs at higher concentrations (25−100 μg/ml) was 
significantly lower than the untreated cells. Incubating human epidermal keratinocytes 
with acid−functionalised SWNTs also showed a dose−dependent reduction in cell 
viability and increased production of the pro−inflammatory cytokine IL−8 [57]. This 
observation could be attributed to the rupture of CNT−contained endosomes that led to 
NLRP3 inflammasome activation and pyroptosis [50, 51].   
It could be suggested that although chemical functionalisation can improve the CNTs 
purity and biocompatibility, the associated increase in CNTs individualisation increased 
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their cellular uptake thus the possibility of causing cytotoxic effects with increased 
dosage. In a similar fashion, Li et al. have demonstrated that as the positivity of 
chemically functionalised MWNTs was increased (by manipulating the surface 
chemistry), the cellular uptake by THP−1 cells (monocytic cell line) and BEAS−2B cells 
(bronchial epithelial cell line) was enhanced causing production of pro−inflammatory 
cytokines [58].  
2.3.2 Biocompatibility with immune cells  
Cytotoxic effects of CNTs on immune cells have been investigated in various studies. 
Using TEM imaging, it was demonstrated that carboxylated SWNTs formed less 
intracellular aggregates following incubation with human monocyte−derived 
macrophages and exerted lower effects on the cell viability than pristine SWNTs [59]. 
Treating murine RAW 264.7 macrophages with pristine SWNTs (26 wt% of iron) led to 
significant depletion of glutathione (oxidative stress biomarker) compared to treatment 
with carboxylated SWNTs (0.23 wt% of iron) [60]. The higher iron content of pristine 
SWNT than carboxylated SWNTs also led to significant increase in the formation of 
intracellular reactive oxygen species following incubation with rat NR8383 macrophages 
[61]. The length of the CNT could also determine the CNTs' biocompatibility. 
LPS−primed, human primary macrophages treated with long pristine MWNT (~13 μm) 
showed higher production of the NLRP3 inflammasome−mediated inflammatory 
cytokine IL−1β than shorter pristine MWNTs (1−10 μm) treated macrophages [51, 62].  
Wang et al. have shown that treating human monocyte−derived DCs with 
carboxylated−MWNTs at 10−100 μg/ml for 48 hr was not associated with a significant 
decrease in cell viability [63]. In addition, the carboxylated−MWNT treatment did not 
increase the DCs expression of the CD80 or CD86 co−stimulatory molecules that 
suggested lack of MWNTs adjuvanticity. However, cytokines production by MWNTs–
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treated DCs was not evaluated in this study. Dumortier et al. have demonstrated that 
culturing mice−derived B or T lymphocytes in the presence of SWNTs functionalised 
using 1,3−dipolar cycloaddition reaction did not induce cell death, provoke cell 
proliferation or stimulate IFN−γ production [64]. Nevertheless, SWNTs functionalised 
via acid−oxidation and amide coupling reactions that exhibited lower aqueous 
dispersibility stimulated the production of TNF−α and IL−6 by macrophages in vitro. 
Although this study highlighted the effect of SWNTs surface chemistry, and 
consequently the aqueous dispersibility, on the cytokine production by immune cells in 
vitro, it would be also useful to investigate the effect of different sized SWNTs.  
Pescatori et al. have also reported that incubating carboxylated or 
amine−functionalised MWNTs with Jurkat T cell line or THP−1 monocytic cell line did 
not induce cell apoptosis [65]. The uptake of the functionalised MWNTs by the THP−1 
monocytic cells, but not the Jurkat T cells, increased the production of IL−6 and TNF−α 
pro−inflammatory cytokines. On the other hand, Medepalli et al. have found that 
DNA−functionalised SWNTs did not alter the cell phenotypes or activation markers 
expression following the incubation with human blood−derived monocytes or 
lymphocytes [66]. Such discrepancy could be attributed to the CNTs' functionalisation 
density, the used doses and incubation time. 
These studies, therefore, suggested that the increased purity of functionalised CNTs 
could be accompanied by improved cytocompatibility. However, functionalised CNTs 
could still exert dose−dependent cytotoxic effects. 
2.4  CNTs' biodistribution 
Biodistribution and clearance of the CNTs are considered among the main obstacles 
clinical application of CNTs is facing. The utilisation of CNTs for the delivery of 
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therapeutic agents demanded studying their biodistribution to determine their organ 
accumulation and toxicity following systemic administration. Yang et al. have 
demonstrated that pristine SWNTs intravenously injected to KM mice were distributed 
mainly to liver, spleen and lung 24 hr post injection [67]. The pristine SWNTs were 
retained in these organs at high levels over a period of 28 days post injection. In addition, 
the pristine SWNTs were un−detectable in the urine or feces samples collected from 
injected mice, which further indicated the retention and accumulation of the injected 
pristine SWNTs in the mentioned organs.            
We have shown that the functionalisation density of MWNTs affected their 
biodistribution and excretion following intravenous injection in BALB/c mice [68]. On 
comparing three types of 111In−radiolabelled MWNTs that were amine−functionalised to 
varying degree, the highest bladder accumulation and lowest liver retention detected at 
0.5 hr and 24 hr post injection, respectively, were demonstrated by the MWNT that 
possessed the highest content of amine moieties. Thus, it was suggested that increasing 
the amine−functionalisation density of MWNTs assisted their individualisation, hence 
glomerular filtration and renal clearance. However, other factors that are, theoretically, 
expected to affect the MWNTs biodistribution such as frequency of administration and 
injected doses were not studied. 
Liu et al. used Raman spectroscopy to qualitatively and quantitatively assess the 
long−term fate of SWNTs functionalised with polyethylene glycol (PEG) of varying 
chain length intravenously administered to BALB/c mice [69]. Raman spectroscopic 
analysis of ex vivo tissues isolated 1 day post−injection of 20 µg SWNTs/mouse showed 
retention of SWNTs−PEG mainly in liver and spleen. The retained SWNTs−PEG, 
especially if functionalised with a long PEG chain, were almost cleared from the liver 
and spleen 3 months after injection with no apparent toxic effects detected in histology 
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specimens and blood chemistry. Administration of higher doses (100 µg/mouse), 
presumably due to improvement in signal−to−noise−ratio, provided evidence of SWNTs 
presence in the bladder and feces at 24 hr post−injection suggesting elimination via the 
renal and biliary routes. On the other hand, the biodistribution and clearance of the 
injected 100 µg SWNTs over longer period of time, e.g. 1 and 3 months, were not 
evaluated. 
Schipper et al. have reported that on monitoring the blood count of nude mice over a 
period of 4 months after the intravenous injection of PEG−functionalised SWNTs, no 
significant differences were detected between the naïve and SWNT−injected mice groups 
[70]. Histological analysis of tissues from the organs excised 4 months post SWNT 
injection showed the presence of dark aggregates that were confirmed by Raman 
spectroscopy to be SWNTs in the liver and spleen macrophages with no obvious 
pathological features. This observation comes despite the fact that mice were injected 
with SWNTs two times (on day 0 and 7), the injected dose of SWNTs was 17 µg/mouse. 
It is quite probably that higher doses of SWNTs as nanocarriers will be required and this 
could be addressed in future work using a similar model.  
Guo et al. studied the biodistribution and excretion of radiolabelled glucosamine− 
functionalised MWNTs following intraperitoneal administration to mice [71]. Tracing 
the radioactivity 1 hr post injection revealed the distribution of MWNTs−glucosamine to 
the main organs and almost complete clearance after 24 hr with less than 70% of the total 
initial radioactivity excreted in urine and feces. However, free radiolabelled glucosamine 
released from the functionalised MWNTs in vivo could provide misleading data about the 
MWNTs biodistribution, thus a more reliable method, e.g. detection of MWNTs Raman 
signals, could have been applied to further support the presented conclusion.         
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 Meng et al. investigated the organ toxicity and immunological reactions induced 
following subcutaneous administration of 1 mg of carboxylated MWNTs to BALB/c 
mice [72]. Histological analysis of heart, liver, kidney and spleen excised from the mice 
over a period of 2 to 90 days post MWNTs injection revealed normal histology with no 
apparent accumulation of MWNTs. However, histological examination of axillary lymph 
nodes excised 30 days post injection showed accumulation of MWNTs that increased and 
then decreased 60 and 90 days, respectively. Nevertheless, the administered MWNTs 
were not completely eliminated and the study did not investigate the fate of the 
accumulated MWNTs. Levels of pro−inflammatory cytokines such as TNF−α and IL−17 
were detected at a higher level in the sera of the MWNT−injected mice compared to 
naïve mice 2 days post injection, however, the cytokine levels returned to normal 7 days 
post injection [72].   
In light of the research gaps highlighted in the mentioned studies, future studies could 
provide more conclusive assessment of the CNTs by considering critical factors such as 
administered doses, frequency of administration, reliability of the methods applied to 
track the injected CNTs and long−term tracking following administration.         
2.5 CNTs' Biodegradability 
Once the loaded cargo is delivered to its intended intracellular target, CNTs need to 
be eliminated from the cells. To this end, there have been growing interests in studying 
the CNTs biodegradability and susceptibility to enzymatic degradation. Allen et al. have 
shown that oxidised SWNTs incubation with the plant−derived horseradish peroxidase 
enzyme at 4 ◦C in the presence of hydrogen peroxide (H2O2) led to length shortening and 
then complete loss of the tubular structure of the SWNTs, as revealed by TEM imaging, 
over a period of 12 weeks [73]. It was suggested that the SWNTs were subjected to 
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biodegradation that was further demonstrated using other methods such as mass 
spectrometry. Despite the harsh conditions applied, complete biodegradation was not 
observed as the TEM images revealed the presence of the carbonaceous material at the 
end of the 12 weeks. In addition, the biodegradation of the SWNTs at conditions 
resembling the intracellular environment was not evaluated. The described mechanism 
behind this degradation relies on the interaction of the peroxidase enzyme with H2O2 to 
generate potent oxidising intermediates that oxidise the CNTs into aromatic oxidised 
fragments and eventually carbon dioxide.  
Kagan et al. have demonstrated that incubating human neutrophil−derived 
myeloperoxidase enzyme and H2O2 with a suspension of oxidised SWNTs in buffered 
saline changed the dark SWNTs suspension into a translucent solution after 24 hr [74]. 
The SWNT biodegradation was assessed by the complete disappearance of the tubular 
SWNT structure in TEM images and the distortion of the characteristic SWNT Raman 
signals. Raman spectroscopic analysis of SWNTs internalised by neutrophils in vitro was 
also used to assess intracellular biodegradation. However, the disappearance of the 
SWNTs characteristic tubular structure or Raman signals cannot be considered as the 
carbonaceous material persists. The study investigated the biocompatibility of the 
carbonaceous material by demonstrating that administration of 40 µg of the biodegraded 
SWNTs via pharyngeal aspiration was not associated with acute pro−inflammatory 
response in mice. Nevertheless, factors such as other administration routes, higher doses 
and possibility of chronic toxicity were not studied. In a similar manner, the same group 
has also studied the biodegradation of oxidised SWNTs following incubation with 
eosinophil peroxidase enzyme and H2O2 or internalisation by murine−derived eosinophils 
in vitro [75]. It would have been interesting to assess the biodegradation of various 
SWNTs doses following incubation with the eosinophils at different time points. 
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Furthermore, the biocompatibility of the persisted carbonaceous material was not 
assessed in vitro or in vivo. 
Interestingly, Shvedova et al. found that pulmonary inflammatory responses induced 
by pharyngeal aspiration of oxidised SWNTs were more intense in myeloperoxidase 
enzyme knockout B6.129X1 mice compared to wild type C57BL/6 mice [76]. The 
authors attributed this observation to the SWNTs intracellular degradation by 
myeloperoxidase enzyme in the C57BL/6 mice. This was supported by the presence of a 
high proportion of SWNTs with shortened length and oxidative defects, in solubilised 
lung sample preparations, 28 days following exposure to the SWNTs as revealed from 
TEM and Raman spectroscopic analysis. However, the carbon material that withstood 
degradation appeared aggregated under TEM and the biocompatibility of the persisted 
material over the long term was not assessed. Moreover, biodegradation of the SWNTs 
following repeated administration or administration via other routes that are more 
frequently used in the biological applications of CNTs, e.g. intravenous or subcutaneous 
injection, were not investigated. 
We have previously studied the degradation of amine−functionalised MWNTs in 
brain tissue following stereotactic brain injection [77]. TEM analysis of mouse brain 
tissue 2 days after the MWNTs administration (0.5 µg/mouse) showed the existence of 
intact cylindrical nanotubes and clustered non−tubular material in the microglia's 
cytoplasm, suggesting MWNTs biodegradation. This observation was further 
investigated via Raman spectroscopic analysis of brain tissues 2 and 14 days post 
MWNTs administration. Decreased intensity was observed in the MWNTs characteristic 
Raman spectra that could be attributed to biodegradation−induced defects, further 
suggesting degradation in brain tissue. However, dose−dependent degradation of the 
MWNTs and the possibility of complete degradation were not investigated.    
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Although the findings of these studies provide evidence for the tendency of CNTs 
towards intracellular biodegradation, the studies did not resolve the issue of the 
carbon−based material cellular persistence. Future studies have to investigate the cellular 
capacity to fully degrade the carbonaceous material and to find out how long would it 
take to completely degrade and eliminate a specified amount of CNTs. Furthermore, 
complete degradation of CNTs should not be the only concern of future studies, as the 
previous studies reported that CNTs biodegradation is achieved by the aid of 
intracellularly−generated reactive oxygen species. Thus, it is also important to carry out a 
long−term assessment of the cellular damage that may occur as a result of the increased 
oxidative stress following cellular uptake of CNTs. 
Biodegradability and elimination can be considered as one of the major hurdles that 
could impede the clinical assessment of CNTs as delivery carriers to therapeutics. In a 
recent study published by Alidori et al., SWNTs functionalised using 1,3−dipolar 
cycloaddition were intravenously administered to non−human primates (cynomolgus 
monkey), the injected SWNTs exhibited biodistribution profile and rapid renal 
elimination in a manner similar to that observed in mice [78]. Despite such encouraging 
results, clinical investigations of the CNTs proficiency as nanocarriers might not be 
possible until pre−clinical assessments of their biosafety, biodegradation and elimination 
are conclusive. In addition, clinical application of functionalised CNTs−based delivery 
systems could be also hindered by the necessity to produce them according to the current 
Good Manufacturing Practices. Hence, several obstacles will need to be overcome in 
order to meet these standards including uniformity of CNTs dimensions, 
functionalisation density and antigen loading. 
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3. Functionalised CNTs as cancer vaccine delivery system 
Various types of particulate carriers have been utilised in vaccine delivery [79-83]. 
The efficacy of particulate vaccines has been assigned to a number of suggested 
mechanisms. Particulate delivery systems can accommodate multiple copies of the 
antigen and adjuvant. Hence, the uptake of particulate vaccine delivery systems by APCs 
could increase the antigen and adjuvant intracellular concentrations, thus the presented 
antigen density.  
Potent anti−tumour immune response induction could be achieved via combinatorial 
therapeutic approaches consisting of tumour antigens and immune modulators capable of 
overcoming tumour−induced immune suppression [6, 84]. Examples of nanoscopic 
particulates previously employed to co−deliver tumour−derived antigen and adjuvant 
include liposomes (spherical vesicles consisting of lipid bilayers enclosing an aqueous 
core) [85], lipopolyplexes (lipid and DNA complex) [86], nanoparticles made up of 
emulsified poly(lactic−co−glycolic acid) (PLGA) [87], virus−like nanoparticles 
(self−assembled capsid protein lacking the viral nucleic acids) [88], albumin−based 
nanoparticles [89] or mesoporous silica nanoparticles (synthetic nanoparticles possessing 
porous structure) [90]. Examples of micro−sized carriers exploited in tumour antigen and 
adjuvant simultaneous delivery are polymeric systems consisting of PLGA [91] or 
diaminosulfide [92] polymers. Despite the differences in the composition and size of 
these nanoparticles or microparticles, they share the property of being spherical in shape. 
The efficacy of particulate delivery systems to deliver cancer vaccines comprised of 
antigen and adjuvant has been investigated in various studies [87, 89-102]. These studies 
have shown that nanoparticles (e.g. liposomes, PLGA nanoparticles or albumin 
nanoparticles) or microparticles (e.g. PLGA or diaminosulfide−based microparticles) 
co−incorporating antigen and adjuvant delayed the growth of cancer cells inoculated in 
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mice. This observation was attributed to the capacity of the nanoparticles or 
microparticles to augment the antigen−specific CD8+ T cell immune response elicited by 
the co−loaded antigen and adjuvant as demonstrated in these studies in vitro or in vivo 
[87, 89-102]. 
Inspired by the demonstrated potentials of the conventional spherical nano−systems 
as vaccine delivery vectors and by the CNTs capacity to enter the cells via different 
mechanisms, various studies have investigated the exploitation of CNTs as vaccine 
nanocarriers. As summarised in Table 1, these studies focused on functionalised CNTs 
using various approaches to deliver antigens expressed by cancer cells and/or adjuvants 
to APCs and tested the efficacy of the CNTs−delivered vaccines through the assessment 
of specific immune responses elicited in vitro and in vivo.  
3.1 Functionalised CNTs as delivery vector for tumour−derived antigen 
As a cancer vaccine delivery system, Sun et al. investigated the use of carboxylated 
MWNTs to deliver MCF7 breast cancer cells−derived tumour lysate protein (TumourP) 
to APCs, specifically the DCs [103]. Flow cytometry showed that the MWNTs improved 
the uptake of the covalently incorporated TumourP by DCs in vitro. Furthermore, DCs 
pre−treated with MWNT−TumourP were more efficient than DCs pre−treated with free 
TumourP in inducing lymphocyte−mediated cytotoxicity against the MCF7 cells in vitro. 
However, the capability of MWNT−TumourP in retarding the MCF7 breast cancer cells 
growth in vivo was not studied. 
Meng et al. assessed the potentials of carboxylated MWNTs to augment the 
anti−tumour immune response elicited against covalently immobilised H22 liver cancer 
cell−derived tumour lysate protein (H22P) [104]. The H22 cells were subcutaneously 
inoculated into BALB/c mice and the mice were subcutaneously injected with 
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MWNT−H22P or free H22P starting 2 days post H22 cells inoculation. The injected 
treatments were further potentiated by the additional administration of inactivated H22 
tumour cells as a tumour cell vaccine. The maximum anti−tumour response was observed 
in mice injected with MWNT−H22P. Lymphocytes isolated from MWNT−H22P injected 
mice showed higher cytotoxicity against the H22 cells in vitro than lymphocytes isolated 
from free H22P−injected mice. Additionally, some of the mice free of H22 tumour, as 
result of MWNT−H22P treatment, successfully inhibited H22 cell growth following 
re−administration. This was due to the induction of antigen−specific memory T cells, 
since challenging 'cured' mice with the unrelated breast cancer cell line EMT led to 
successful tumour growth. The authors suggested that the augmented antigen−specific 
immune response elicited by MWNT−H22P was due to increased uptake of 
MWNT−conjugated H22P by the APCs, however, the MWNTs ability to enhance 
antigen uptake by the APCs in vivo was not tested. In addition, to evaluate the therapeutic 
efficiency of MWNT−H22P, it would have been informative to treat H22−tumour 
bearing mice with the vaccine rather than to challenge mice with tumour cells post 
vaccination.
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Table   1. Summary of the studies investigated the use of CNTs as vaccine delivery systems.  
CNT Antigen (conjugation) 
Adjuvant 
(conjugation) 
Significant outcome(s) Refs 
Carboxylated MWNT 
MCF7 breast cancer cells−derived 
tumour lysate (covalent) 
− 
− Increased antigen uptake by DCs in vitro. 
− Improved the induction of tumour−specific T cell response by DCs in vitro. 
[103] 
Carboxylated MWNT 
H22 liver cancer cells−derived 
tumour lysate (covalent) 
− 
− Increased antigen−specific CTL response in mice. 
− Increased the cure rate of H22 tumours subcutaneously inoculated in mice. 
[104] 
Amine−functionalised 
SWNT 
Wilms' tumour protein−derived 
peptide (covalent) 
− − Increased the serum levels of peptide−specific IgG in mice. [105] 
Polyethylene 
glycol−functionalised 
SWNT 
− CpG (non−covalent) 
− Increased the CpG cellular uptake and CpG−mediated cytokine production by 
bone marrow−derived monocytes in vitro. 
− Delayed the growth of GL261 glioma intracranially implanted in mice. 
[106] 
Carboxylated MWNTs 
OVA or tumour−derived 
NY−ESO−1 (non−covalent) 
CpG (non−covalent) 
− Increased IFN−γ production by ex vivo stimulated splenocytes isolated from 
immunised mice spleen. 
− Increased the serum levels of antigen−specific IgG in mice.  
− Delayed the NY−ESO−1−B16F10 tumour growth in subcutaneous tumour 
model. 
[107] 
Carboxylated and  
amine−functionalised 
MWNTs 
OVA 
CpG and αCD40 
(non−covalent) 
− Increased CD8+ T cells proliferation and IFN−γ production in vitro. 
− Increased antigen−specific CTL response in mice. 
− Delayed the OVA−expressing B16F10 tumour growth in subcutaneous tumour 
model and prolonged survival. 
− Delayed the OVA−expressing B16F10 tumour growth in lung 
pseudo−metastatic tumour model.  
[108] 
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In order to potentiate the immune response elicited by the poorly immunogenic Wilms' 
tumour protein (WT1) Villa et al. covalently conjugated WT1−derived peptide with 
amine−functionalised SWNTs [105]. The SWNTs were internalised by the DCs in vitro, as 
determined using live confocal imaging, with no effects exerted on cell viability. The free WT1 
peptide or SWNT−WT1 peptide conjugate were mixed with an oil−based adjuvant and then 
subcutaneously administered to BALB/c mice. The highest levels of anti−WT1 peptide IgG were 
detected in the sera collected from mice vaccinated with SWNT−WT1 peptide. However, tumour 
therapy experiments using WT−1 expressing cells were not carried out.  
3.2 Functionalised CNTs as delivery vector for adjuvants 
Appropriate activation of APCs is crucial for unlocking their full T cell stimulatory capacity 
[109]. Innate activation of APCs is mediated by pattern recognition receptors (PRRs) such as 
Toll−like receptors (TLRs), C−type lectin receptors (CLRs) and NOD−like receptors (NLRs) 
[110, 111]. These receptors recognise ligands associated invading pathogens known as 
pathogen−associated molecular patterns (PAMP). Naturally occurring PAMPs or their synthetic 
analogues have been widely explored in vaccine formulations as adjuvants with the aim to 
promote immunity induction [111, 112]. In particular, synthetic TLR9 agonists in form of 
oligodeoxynucleotides (ODN) containing unmethylated deoxycytidine−deoxyguanosine 
dinucleotide (CpG) motifs have been included as adjuvant in many clinically investigated cancer 
vaccine formulations (Fig. 3.) [113, 114]. 
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Fig. 3. Immune stimulatory activities of CpG. Stimulation of the DCs' TLR9 by CpG induces DC 
maturation by upregulating the MHC, CD40 and CD86 expression, and provokes the immune stimulatory 
cytokines production that ultimately determines the DC ability to induce CD4+ and CD8+ T cells priming. 
The figure is modified from ref [115]. 
 
 
The delivery of TLR9 agonist to APCs using CNTs has also been studied. Zhao et al. 
investigated whether SWNT−mediated delivery of CpG ODN could enhance the cellular uptake 
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and the immune stimulatory properties of the vaccine and promote potent anti−tumour immune 
response induction [106]. The authors showed that the uptake of fluorescently labelled CpG by 
bone marrow−derived monocytes in vitro was increased by its non−covalent conjugation to 
SWNTs. The SWNT−CpG conjugate also increased the CpG−induced production of interleukin 
(IL)−12 and tumour necrosis factor (TNF)−α by the monocytes in vitro. Moreover, intratumoural 
injection of the SWNT−CpG conjugate effectively delayed the growth of GL261 glioma cells 
intracranially−implanted in mice, which was not observed in mice injected with SWNT alone or 
free CpG. SWNT−CpG treatment failed to delay the growth of GL261 glioma cells intracranially 
implanted into mice depleted of CD8+ T cells or natural killer cells. This observation indicates 
the joint involvement of these cells in the induction of anti−tumour immune responses by 
SWNT−CpG conjugate. 
Fan et al. have reported that intracranial administration of SWNT−CpG could also inhibit 
metastatic tumour growth in C57BL/6 mice [116]. This was demonstrated by showing that 
injection of SWNT−CpG was more efficient than free CpG in delaying the growth of 
subcutaneous and intracranial inoculated B16F10 melanoma cells. Furthermore, testing the 
therapeutic efficacy against a more challenging glioma model, Ouyang et al. have shown that 
SWNT−CpG along with the chemotherapeutic drug temozolomide, intratumorally administered, 
to mice bearing intracranial K−Luc glioma cells led to significantly prolonged survival in 
contrast to the injection of free CpG and temozolomide [117].       
3.3 Functionalised CNTs as delivery vector for both tumour−derived antigen and 
adjuvants            
In 2014 Faria et al. have reported the delivery of antigen and adjuvant to APCs using CNTs 
[107]. In this study the model antigen OVA and the TLR9 agonist CpG were both 
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non−covalently linked to carboxylated MWNTs. Mice immunised with MWNT−conjugated 
OVA and CpG showed higher sera levels of anti−OVA IgG and IFNγ production by ex vivo 
stimulated splenocytes than mice immunised with free OVA and CpG. The authors also tested 
the ability of the carboxylated MWNTs to co−deliver NY−ESO−1 (tumour antigen expressed in 
various human cancers) in combination with CpG to the APCs. The immune response induced in 
vivo by NY−ESO−1 and CpG was intensified following their non−covalent linkage to MWNTs. 
In addition, testing the ability to induce protective immunity, mice pre−injected with 
NY−ESO−1 and CpG−loaded MWNTs demonstrated a markedly retarded growth of 
NY−ESO−1 expressing B16F10 melanoma cells in subcutaneous tumour model. However, to 
assess the therapeutic efficacy of the designed MWNT−based vaccine, tumour−inoculated mice 
were vaccinated three days post tumour cell inoculation, when tumour growth was still 
undetectable. Therefore, it is unclear whether therapeutic vaccination with carboxylated MWNTs 
co−delivering antigen in combination to CpG ODN would lead to effective remission of a well 
establish tumour.  
In a previous study, we compared the efficacy of MWNTs functionalised using 1,3−dipolar 
cycloaddition, oxidation or amide coupling reactions in delivering non−covalently immobilised 
OVA to APCs [118]. The MWNTs functionalised via amide coupling were more efficient in 
enhancing the OVA−specific immune response both in vitro and in vivo. In a follow−up study, 
the functionalised MWNT possessing surface chemistry that was found optimal for OVA 
delivery was then utilised for the co−delivery of OVA along with the adjuvants CpG and 
anti−CD40 antibody (αCD40) to the APCs in form of a (αCD40)MWNT(OVA−CpG) conjugate 
[108]. In addition to the immune stimulatory properties that can be acquired by the inclusion of 
αCD40 [84, 119, 120], we hypothesised that αCD40 contained in the aforementioned conjugate 
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will target it to the CD40 receptor on APCs, including cross−priming DC subsets, and thereby 
further enhance antigen cross−presentation to CD8+ T cells. Previous studies have demonstrated 
the ability αCD40−antigen conjugates to mediate uptake via CD40 receptor and enable 
translocation of the conjugate to the early endosomes [121-123]. It has been suggested that 
antigen translocation to early endosomes could support antigen escape into the cytosol and 
thereby promote antigen cross−presentation (Fig. 4.). It was observed that DCs treated with 
(αCD40)MWNT(OVA−CpG) in vitro possessed significantly lower surface expression of CD40 
receptor compared to DCs treated with MWNT(OVA−CpG). This finding could support the 
hypothesis that CD40 receptor was internalised following its ligation with the αCD40 contained 
in (αCD40)MWNT(OVA−CpG) [121, 122]. However, to conclusively support this hypothesis it 
would be interesting to investigate the intracellular trafficking of the CD40 receptor following 
the incubation of DCs with (αCD40)MWNT(OVA−CpG). Antigen presentation to CD8+ T cells 
in vitro was more efficient when DCs were treated with (αCD40)MWNT(OVA−CpG) compared 
to treatment with free αCD40 in combination with MWNT(OVA−CpG). The 
(αCD40)MWNT(OVA−CpG) conjugate also amplified the OVA−specific CTL response in vivo 
at reduced OVA and CpG doses. Lastly, (αCD40)MWNT(OVA−CpG) demonstrated significant 
proficiency in delaying tumour growth in the subcutaneous and lung pseudo−metastatic 
B16F10−OVA tumour models. However, it is unclear whether antigen−specific memory was 
induced in this model since tumour−inoculated mice treated with (αCD40)MWNT(OVA−CpG) 
that remained tumour−free were not re−challenged with B16F10−OVA tumour cells. 
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Fig. 4. Impact of intracellular routing of antibody−conjugated antigen on antigen presentation.  
Delivering antigens through a linked targeting antibody to a specific receptor expressed by APCs is 
followed by cellular internalisation of the formed cargo. Relying on the targeted receptor, the internalised 
cargo could be routed to a specific intracellular compartment. For instance, it has been found that 
mannose and CD40 receptors are intracellularly routed to the early endosomes, whereas CD205 receptor 
is routed to the late endosomes. In the late lysosome−containing endosomes, internalised antigen is 
subjected to rapid degradation by the lysosomal enzymes and presentation of the processed antigenic 
fragments via MHC class II molecules. In the early endosomes, the slow rate by which antigen is 
degraded could facilitate antigen escape from the endosomal to cytosolic compartments that allows 
proteasomal antigen degradation and, subsequently, presentation via the MHC class I molecules. The 
thicker arrow denotes that this route of presentation of processed antigen is more predominant than the 
other pathway. The figure has been re−drawn from ref [123]. 
 
4. Future perspective of CNTs as vaccine delivery systems  
As with as all cancer vaccines their success, or failure, is dependent on finding the right 
combination of antigen, adjuvant and delivery vehicle. The future of CNTs as a delivery 
platform/adjuvant is dependent on their relative potency compared to other modalities while the 
future of the field itself is inextricably linked to the identification of novel antigens or vaccine 
regimes. In the immediate future, CNTs need to be comprehensively assessed against other 
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vaccine formulations to establish where they belong on the ‘spectrum of adjuvanticity’. These 
studies are seldom performed (or at least seldom published) on novel adjuvant candidates due to 
the fear of coming up short against current formulations and thus losing funding/interest. 
However, it has made assessing whether an adjuvant is clinically viable over an alternate, near 
impossible.           
Whether the outcome of these studies is positive or negative it should be noted CNTs 
have two distinct advantages over traditional adjuvants; the first is their mode of entry into cells. 
As previously reviewed CNTs have direct access to the cytosol through the proposed nano− 
needle mechanism. The implications of this in the context of vaccine adjuvants should not be 
understated. The ability to initiate a strong cytotoxic MHC class I restricted immune response to 
a soluble antigen has been seen as the Holy Grail for vaccine adjuvants. This is especially the 
case for cancer vaccines but also for vaccines against certain infectious agents [124, 125]. In 
addition, efficient delivery of payload to the cytosol may make other types of vaccines, 
specifically nucleic acid based vaccine including DNA and recently mRNA vaccines, more 
viable. The nano−needle mechanism is poorly understood with many groups reporting differing 
outcomes following administration of CNTs depending on a multitude of factors such as surface 
chemistry, size and aspect ratios as previously discussed. The first step in the rational design of a 
CNT based delivery vehicle should be the systematic evaluation of physical traits and surface 
modifications in order to improve cytosolic delivery. Our group has looked into some of the 
modifications of CNTs and has shown that relatively minor changes in structure can cause vast 
differences in immunogenicity though we have not been able to attribute this to improved 
cytosolic delivery [118]. Future work should continue and expand upon this.      
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The second key advantage of CNTs over traditional carriers is their large surface area. 
According to the current rationale for the use of CNTs, this enables the delivery of large amounts 
of antigen/adjuvant to APCs. Expanding on this theory, it has recently been shown that 
particulates can bind to antigen within the tumor environments following intratumoral 
inoculation [126]. For instance, Min et al. recently demonstrated that an injection of nanoparticle 
intratumorally, prior to radio ablation of the tumour, served to enhance the so called ‘abscopal 
effect’: the phenomenon whereby following the ablation of a tumour a systemic immune 
response is triggered against the released antigen/immune stimulants resulting in remission of 
distal tumours. One hypothesis is that the particles are retained within the tumour ‘mopping up’ 
antigen and immune active molecules. When the tumour is subsequently ablated the particles are 
released and are taken up by APCs in the tumour−draining lymph nodes [126]. The high surface 
area of the CNTs and the ability to form strong non−covalent associations with proteins 
specifically lends them to this purpose. Indeed it has been shown that GO formulated with CpG 
can be used for photothermal ablation, though the assessment of the abscopal effect was not 
measured, there is clearly an immune component [127]. There have been some studies assessing 
the ‘protein corona’ following administration of CNT intravenously, it would be interesting to 
perform these studies following intra−tumoral administration to determine how much tumour 
antigen can be absorbed directly from the tumour tissue in comparison to other carriers [128, 
129]. Supporting this general hypothesis, it has been shown that CNTs, when formulated in vitro 
with tumour cell lysate, can serve to protect from tumour challenge [130].          
Another intra−tumoral approach is the concept of ‘in situ’ vaccination.  Here an agent is 
injected into the tumour leading to activation of the immune system to antigens present on the 
tumour/in the microenvironment. This relatively simple concept has led to miraculous results 
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preclinically, notably the use of CpG and anti−OX40 in combination is particularly potent [131]. 
It would be interesting to compare anti−OX40 to anti−CD40 antibody plus CpG in combination 
with CNT in a preclinical model to identify which approach is more efficient in eliciting 
anti−tumour immunity. It also would be interesting to compare the efficacy of synthetic CNT 
vaccines to biological vaccines such as plant virus−based vaccines. Filamentous and spherical 
plant viruses have been explored as in situ vaccines [132, 133]. In contrast to plant viruses, 
which are complex biological entities, CNTs may provide a better−controllable synthetic 
platform to explore the relationship between morphology and immunogenicity. In addition, CNT 
vaccines allow different combinations of TLR agonists to be used, and thereby enables the 
dissection of the requirements for optimal formulation.  
In more general terms, it is likely that all future cancer vaccine candidates will be trialed 
in combination with a checkpoint inhibitor at some stage during their clinical assessment. To 
date, two checkpoint inhibitors have been clinically approved and these are targeted against 
inhibitory molecules PD−1 and CTLA4 and their purported mechanism has been reviewed 
elsewhere [15]. However, new classes of stimulatory checkpoint molecules including agonistic 
anti−OX40 and anti−4−1−BBL antibodies are showing efficacy in preclinical trials [120]. This 
has led to the concept of an ‘immune switch’; this is a biomaterial containing both an immune 
stimulatory antibody at well an anti−inhibitory antibody [134]. In this study the authors show 
that the immune switch is more potent than either of the two antibodies when administered in 
their soluble form. Again, due to their high surface area and ease at forming non−covalent 
attachments to proteins, CNTs could be the preferred vehicle for this purpose. Other than 
checkpoint blockade it could be argued that the generation of personalised vaccines becomes 
more feasible as DNA sequencing becomes faster and cheaper. The antigenic payload of 
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personalised vaccines will likely be peptides or nucleic acid due to ease of synthesis and quality 
control. However, both of these modalities are typically poorly immunogenic and require a 
delivery platform and adjuvant. In a proof of concept study the group of Kuai et al. sequenced 
murine tumours to detect mutations and these neo peptides were synthesised and loaded on to 
lipid nano discs [135]. The resulting particles were shown to protect against tumour challenge. In 
this approach it could be envisioned that the adjuvant/delivery platform will be prepared in a 
ready to use ‘off the shelf’ format and simply mixed with individual tumor neo antigens as 
determined by high throughput sequencing. CNTs represent a candidate platform for this 
approach as they can be synthesised in bulk and stored for long durations with little degradation, 
furthermore they can be made positively charged or amine reactive for binding of nucleic acid or 
peptide respectively as previously discussed.         
5. Conclusions 
The better understanding of tumour immunology has allowed development of cancer 
vaccines. However, tumour−induced immunosuppression has constituted a major hurdle to the 
capacity of these formulations to enhance the immune response. Attempts applied to augment 
anti−tumour immune response potency have included the delivery of the aforementioned vaccine 
formulations via nano−carriers. CNTs demonstrated characteristic cellular uptake properties that 
encouraged the exploitation of their nano−needle properties. Pre−clinical studies highlight that 
CNTs represent a competent cancer vaccine delivery system. Nevertheless, future studies are 
required to investigate the uniqueness that theses CNTs possess as vaccine carrier over other 
vectors such as for example liposomes. In addition, despite the encouraging results reported in 
pre−clinical studies, clinical studies are hindered by the conflicting reports on CNTs 
biocompatibility and biodegradability. Finally, fortification of the vaccine formulations via the 
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inclusion of multiple adjuvants, APCs targeting ligands and combining this approach with a 
checkpoint inhibitor, could dramatically reduce the required CNTs doses and encourage their 
clinical assessment.   
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Table   1. Summary of the studies investigated the use of CNTs as vaccine delivery systems.  
CNT Antigen (conjugation) 
Adjuvant 
(conjugation) 
Significant outcome(s) Refs 
Carboxylated MWNT 
MCF7 breast cancer cells−derived 
tumour lysate (covalent) 
− 
− Increased antigen uptake by DCs in vitro. 
− Improved the induction of tumour−specific T cell response by DCs in vitro. 
[101] 
Carboxylated MWNT 
H22 liver cancer cells−derived 
tumour lysate (covalent) 
− 
− Increased antigen−specific CTL response in mice. 
− Increased the cure rate of H22 tumours subcutaneously inoculated in mice.  
[102] 
Amine−functionalised 
SWNT 
Wilms' tumour protein−derived 
peptide (covalent) 
− − Increased the serum levels of peptide−specific IgG in mice. [103] 
Polyethylene 
glycol−functionalised 
SWNT 
− CpG (non−covalent) 
− Increased the CpG cellular uptake and CpG−mediated cytokine production by 
bone marrow−derived monocytes in vitro. 
− Delayed the growth of GL261 glioma intracranially implanted in mice.  
[104] 
Carboxylated MWNTs 
OVA or tumour−derived 
NY−ESO−1 (non−covalent) 
CpG (non−covalent) 
− Increased IFN−γ production by ex vivo stimulated splenocytes isolated from 
immunised mice spleen. 
− Increased the serum levels of antigen−specific IgG in mice.  
− Delayed the NY−ESO−1−B16F10 tumour growth in subcutaneous tumour 
model. 
[105] 
Carboxylated and  
amine−functionalised 
MWNTs 
OVA 
CpG and αCD40 
(non−covalent) 
− Increased CD8+ T cells proliferation and IFN−γ production in vitro. 
− Increased antigen−specific CTL response in mice. 
− Delayed the OVA−expressing B16F10 tumour growth in subcutaneous tumour 
model and prolonged survival. 
− Delayed the OVA−expressing B16F10 tumour growth in lung 
pseudo−metastatic tumour model.  
[106] 
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